These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7198457)

  • 21. Pharmacological activities and side effects of plafibride.
    Gras J; Basi N; Zapatero J; Bermejo P; Gimenez F; Beascoa E; Llenas J; Bargalló MA; Giráldez A; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1808-16. PubMed ID: 6976173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
    Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain.
    Calatayud JM
    Methods Find Exp Clin Pharmacol; 1983 Dec; 5(10):707-14. PubMed ID: 6672489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
    Johnson KI; Hoppe HJ; Schatton W
    Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H; Rothley D; Ewert M; Nachev P
    Arzneimittelforschung; 1980; 30(6):984-8. PubMed ID: 7191278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of vascular insufficiency of the legs with plafibride].
    Lázaro Campillo T; Gesto Castromil R; de la Sierra L; Pujadas J; Villafana W; Moreno R
    Med Clin (Barc); 1984 Dec; 83(18):752-5. PubMed ID: 6521538
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapy of ischemic ulcers of the lower extremities using plafibride].
    Palou Monzo J; López-Delmás FJ
    Angiologia; 1984; 36(6):273-8. PubMed ID: 6517385
    [No Abstract]   [Full Text] [Related]  

  • 30. Bioavailability studies of etofibrate in rhesus monkeys.
    Waller AR; Chasseaud LF; Taylor T; Schatton W
    Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plafibride (ITA 104).
    Arzneimittelforschung; 1981; 31(10a):1781-866. PubMed ID: 7198454
    [No Abstract]   [Full Text] [Related]  

  • 32. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 33. [Amino acid derivatives of 2-(p-chlorophenoxy)-2-methylpropionic acid as compounds with potential antilipemic agents. II. Preparation of methyl esters of N-[2-(p-chlorophenoxy)-2-methylpropionyl] amino acids].
    Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1987; 44(2):121-31. PubMed ID: 3434313
    [No Abstract]   [Full Text] [Related]  

  • 34. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrate.
    Vazquez Lopez F; Armijo Castro F; Pire Solis I; Gutierrez Fuentes JA
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):31-5. PubMed ID: 3557726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Plafibride and vascular insufficiency of the lower limbs].
    Soringer Escofet FJ; Esteva de Antonio I
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999856
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 38. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R
    Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926
    [No Abstract]   [Full Text] [Related]  

  • 39. [Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2].
    Lasierra J; Díez MM; Fernández A; Viladés E; Gil M; Velázquez E
    Sangre (Barc); 1983; 28(6):687-95. PubMed ID: 6424250
    [No Abstract]   [Full Text] [Related]  

  • 40. Biopharmaceutic evaluation of etofylline clofibrate and its drug formulation.
    Ritschel WA; Thompson GA; Lücker PW; Wetzelsberger K
    Arzneimittelforschung; 1980; 30(11b):2020-3. PubMed ID: 7194052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.